Clinical Trial Update: A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and combination immunotherapy trial evaluating BMS-986226 alone or with nivolumab or ipilimumab in advanced solid tumors was terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignancy
• Neoplasm
• Tumor

Drugs mentioned

• BMS-986226 (BMS-986226)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cancer, Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-02-28